IE
BCRX icon

Israel Englander’s BioCryst Pharmaceuticals BCRX Stock Holding History

Israel Englander’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-56,800
Closed -$474K – 6115
2023
Q1 		$474K Buy
+56,800
New +$547K ﹤0.01% 4641

Other funds holding BCRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

Israel Englander's BCRX Position: Q2 2026 in Review

Israel Englander increased its BioCryst Pharmaceuticals (BCRX) stake by 1,708% in Q2 2026, buying an estimated $29M and bringing the position to 3,394,729 shares worth $33.9M. The position accounts for 0.01% of the portfolio, ranked #1177.

Israel Englander first reported a position in BCRX in Q3 2013 and has held it in 51 quarters since. The position peaked at $37.3M in Q2 2023. 316 funds tracked by Wall St. Rank hold BCRX as of Q2 2026.

  • Israel Englander held 3,394,729 shares of BioCryst Pharmaceuticals worth $33.9M as of Q2 2026.
  • Israel Englander bought 3,207,008 BioCryst Pharmaceuticals shares in Q2 2026, an estimated $29M.
  • BioCryst Pharmaceuticals made up 0.01% of Israel Englander's portfolio in Q2 2026, its #1177 holding.
  • Israel Englander first reported a position in BioCryst Pharmaceuticals in Q3 2013 and has held it in 51 quarters since.
  • Israel Englander's BioCryst Pharmaceuticals position peaked at $37.3M in Q2 2023.
  • 316 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q2 2026.

Based on Millennium Management's 13F filing for Q2 2026, filed 14 Aug 2026.